Endocrine treatment of breast cancer is as follows: 1, estrogen receptor modulators: can be used in patients before and after menopause, such as tamoxifen, toremifene, fulvestrant, etc.; 2, aromatase inhibitors: limited to postmenopausal patients, such as letrozole, anastrozole, exemestane, etc., with the side effect of aggravating the symptoms of osteoporosis; 3, ovarian deprivation drugs: for premenopausal female patients, such as goserelin and other drugs; 4, the presence of risk factors recommended the use of ovarian function inhibiting drugs superimposed on tamoxifen or goserelin for the treatment of breast cancer. Such as goserelin and other drugs; 4, the presence of high risk factors of premenopausal female patients, recommended the use of ovarian function inhibition drugs superimposed on tamoxifen or aromatase inhibitors for treatment. The specific use of drugs should be combined with the clinical, by the doctor’s interview guidance shall prevail.